Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Icl Group Ltd (ICL) vs Johnson & Johnson (JNJ) Price & Performance

Icl Group LtdTrade
Johnson & JohnsonTrade

Price performance (Past 24H)

Key statistics

Icl Group Ltd vs Johnson & Johnson — how do they compare? Icl Group Ltd trades at $5.02 (market cap $6.47B), while Johnson & Johnson trades at $261.44 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 95.5× Icl Group Ltd's market cap, and Icl Group Ltd pays the higher dividend (4.11%). Which is the better fit depends on your goals — on Pluang, investors hold Icl Group Ltd for 56 Days and Johnson & Johnson for 129 Days on average.

ICLJNJ
Market Cap
$6.47B$618.09B
Volume
1,387,1406,050,983
Sector
Basic MaterialsHealth
52-Week High
$6.84$278.43
52-Week Low
$4.80$186.00
Typical Hold Time
56 Days129 Days
Enterprise Value
$9.11B$646.37B
Dividend Yield
4.11%2.09%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Icl Group Ltd

ICL trades at $5.02, down 1.18% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $0.12, beating estimates, but revenue and net income have declined from 2022 peaks. Valuation appears reasonable with P/E of 20.83 and P/S of 0.84, while analyst consensus is entirely Hold with a $6.08 price target. Recent news highlights dividend strength and cost-transformation initiatives.

The outlook is mixed: earnings beats and dividend yield offer support, but declining profitability and industry headwinds pose challenges. Upside exists if cost cuts and price stabilization materialize, though margin pressure and competitive threats remain key risks for investors.

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).

JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

ICL

No sentiment data available yet.

JNJ
82% Buy18% Sell
Avg holding period · 129 Days

Top news

Latest headlines on both assets

About Icl Group Ltd

ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.

Read more on ICL →

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ →